These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39021330)

  • 1. Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study.
    Zhao L; Zeng Q; Zhou X; Tang L; Wang Y; Han Q; Zou Y; Xiao X; Liu K; Ju X; Wu Y; Li X; Zhao C; Liu F
    Diabetes Obes Metab; 2024 Oct; 26(10):4241-4250. PubMed ID: 39021330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
    Hydes TJ; Kennedy OJ; Buchanan R; Cuthbertson DJ; Parkes J; Fraser SDS; Roderick P
    BMC Med; 2023 May; 21(1):185. PubMed ID: 37198624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.
    Delgado GE; Kleber ME; Moissl AP; Yazdani B; Kusnik A; Ebert MP; März W; Krämer BK; Lammert A; Teufel A
    Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G252-G261. PubMed ID: 34132110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Seo DH; Suh YJ; Cho Y; Ahn SH; Seo S; Hong S; Lee YH; Choi YJ; Lee E; Kim SH
    Diabetes Metab J; 2022 Jul; 46(4):630-639. PubMed ID: 35081304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated small dense low-density lipoprotein-cholesterol and the risk of kidney and cardiovascular outcomes in diabetic kidney disease.
    Yang Q; Zou Y; Lang Y; Yang J; Wu Y; Xiao X; Qin C; Zhao Y; Liu F
    Ren Fail; 2024 Dec; 46(2):2369701. PubMed ID: 38952279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
    Chinnadurai R; Ritchie J; Green D; Kalra PA
    Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes.
    Leite NC; Cardoso CRL; Salles GF
    J Diabetes Complications; 2021 May; 35(5):107879. PubMed ID: 33573891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study.
    Liu N; Wang G; Liu C; Liu J; Huang S; Zhou Y; Xiao E
    Diabetes Obes Metab; 2023 Feb; 25(2):365-376. PubMed ID: 36181433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
    Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
    Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.